D
D Wrench
Researcher at St Bartholomew's Hospital
Publications - 4
Citations - 1591
D Wrench is an academic researcher from St Bartholomew's Hospital. The author has contributed to research in topics: Internal medicine & Rituximab. The author has an hindex of 1, co-authored 1 publications receiving 1416 citations.
Papers
More filters
Journal ArticleDOI
Stromal gene signatures in large-B-cell lymphomas
Georg Lenz,George E. Wright,Sandeep S. Dave,Wenming Xiao,Jonathan D. Powell,Hong Zhao,Weihong Xu,Bruce K. Tan,Neta Goldschmidt,Javeed Iqbal,Julie M. Vose,Martin Bast,Kai Fu,Dennis D. Weisenburger,Timothy C. Greiner,James O. Armitage,Alastair H. Kyle,Lorraine May,Randy D. Gascoyne,Joseph M. Connors,Gunhild Trøen,Harald Holte,Stein Kvaløy,Daan Dierickx,Gregor Verhoef,Jan Delabie,Erlend B. Smeland,Pedro Jares,A. Martinez,Armando López-Guillermo,Emili Montserrat,Elias Campo,Rita M. Braziel,Thomas P. Miller,Lisa M. Rimsza,James R. Cook,Brad Pohlman,John Sweetenham,Raymond R. Tubbs,Richard I. Fisher,Elena Hartmann,Andreas Rosenwald,German Ott,German Ott,H-K Muller-Hermelink,D Wrench,T. A. Lister,Elaine S. Jaffe,Wyndham H. Wilson,Wing C. Chan,Louis M. Staudt +50 more
TL;DR: Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment, and a multivariate model created from three gene-expression signatures predicted survival both in patients who received CHOP and patients who receive R-CHOP.
Journal ArticleDOI
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
M. Northend,William R. Wilson,Wendy Osborne,Christopher P. Fox,Andrew Davies,Dima El-Sharkawi,Elizabeth J. Phillips,Hau Wui Sim,Shalal Sadullah,Nimish Shah,Ying Ying Peng,Iman Qureshi,J Addada,R. F. Mora,Neil Phillips,Andrea Kuhnl,Elizabeth Davies,D Wrench,Pamela McKay,I Karpha,Anna Cowley,Richard Karim,S Challenor,V. V. Singh,C. Burton,Rebecca Auer,Christopher Williams,Joel Cunningham,Angus Broom,Anita Arasaretnam,Claire Roddie,Tobias F. Menne,William Townsend +32 more
TL;DR: Empirical data demonstrate efficacy for Pola-BR as a treatment for SCT-ineligible patients with R/R DLBCL, help to delineate which patients may benefit most, and provide preliminary evidence of efficacy as bridging to CAR T-cell therapy and after CAR-T failure.
Journal ArticleDOI
P1141: ibrutinib and rituximab as first line therapy for mantle cell lymphoma: a multicentre, real-world uk study
A. M. Tivey,Rohan Shotton,Toby A. Eyre,David J. Lewis,Nicola Crosbie,Emma Nga,R. Guerrero Camacho,Wint Swe,Helen Marr,Charlotte Rees,Sharon Moule,T. Sutton,D Wrench,Natasha Thomas,Mark Wilson,Johnathan Bailey,Mahesh Prahladan,A. Hodson,M. Koppana,S. Smith,Stephanie Jones,Fiona Miall,Jane Norman,E. Davies,Catherine Hildyard,Lisa Lowry,Shankara Paneesha,Iman Qureshi,Amy Beech,Carmen Bedford,A Everden,David L. Tucker,J D Wright,John Goddard,Toby Nicholson,J. Wilson,Amanda Lord,B. Jackson,Marcin Flont,Adam Gibb,Kim Linton +40 more
TL;DR: The real-world response rates (overall response rate (ORR), complete response (CR) rate) and toxicity profile of IBR +/-R in adult patients with previously untreated MCL and Nordic-treated patients are described.